

## DIASORIN S.P.A. – UPDATE 2022 ANNUAL CALENDAR OF CORPORATE EVENTS\*

**Saluggia, April 8, 2022** – Partially updating the notice submitted on December 21, 2021, please find below the annual calendar of corporate events, including the new scheduled date for approval of the interim financial statements related to the first quarter 2022.

### **Board of Directors**

<b>May 6, 2022</b>	<b>First Quarter 2022 results</b> approval
<b>July 29, 2022</b>	<b>Half-Yearly Financial Report</b> approval
<b>November 10, 2022</b>	<b>Third Quarter 2022 results</b> approval

### **Shareholders' Meeting**

<b>April 29, 2022</b>	<b>Annual General Meeting</b> for: (i) Statutory Financial Statements 2021 approval; (ii) Report on the remuneration policy and fees paid approval; (iii) election of corporate bodies.
-----------------------	---

\* Indicative dates subject to change. Any changes will be communicated without delay.

In addition, the Company notifies that the month envisaged for the payment of any dividend in relation to 2021 results is May 2022. The information herein reported is given for the exclusive purpose of complying with the relevant Borsa Italiana S.p.A. regulations and cannot be interpreted or considered in any way as a forecast on the occurrence of the requirements for the distribution of dividends.

### **For additional information, please contact:**

**Riccardo Fava**  
*Corporate Vice President Communication & Investor Relations*  
 Tel: +39.0161.487988  
[riccardo.fava@diasorin.it](mailto:riccardo.fava@diasorin.it)

**Emanuela Salvini**  
*Investor Relator*  
 Tel: +39.0161.487567  
[emanuela.salvini@diasorin.it](mailto:emanuela.salvini@diasorin.it)

### **About DiaSorin**

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 45 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist". More info at [www.diasoringroup.com](http://www.diasoringroup.com)